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Development and Implementation of an Anthropomorphic Head & Neck Phantom 
for the Assessment of Proton Therapy Treatment Procedures 
By: Daniela Branco, B.S.    
Chair of Advisory Committee: David Followill, Ph.D. 
Proton therapy has been used to treat cancer for more than 50 years, and over the 
past decade, its use has grown rapidly. One of the main goals of modern radiation 
therapy is to deliver a high dose to the planning target volume (PTV) with minimal 
exposure and damage to the surrounding healthy tissue. Protons offer a unique 
advantage over photon radiotherapy in that they deposit dose over a finite range, in 
contrast to the more gradual energy deposition of photon and electron beams. At present, 
23 proton centers are in operation in the United States and another 13 centers are in 
development. The increasing interest in the use of protons creates a demand for quality 
monitoring and evaluation of the treatments provided, especially as they apply to NCI 
funded clinical trials. The goal of the Imaging and Radiation Oncology Core (IROC) 
Houston QA Center is to assure NCI that institutions participating in clinical trials 
deliver radiation treatment plans/doses that are clinically comparable and consistent. 
IROC Houston makes use of anthropomorphic QA phantoms in order to help verify the 
quality of the proton treatment process from imaging to treatment delivery. With new 
Head and Neck (H&N) proton therapy trials being developed, IROC Houston needs a 
H&N proton phantom that can be used as part of credentialing. Therefore, the hypothesis 
of this study is that an anthropomorphic H&N phantom can be designed and built to 
evaluate proton therapy H&N treatment procedures that can reproducibly (±3%) assure 
agreement between the measured doses and calculated doses to within ±7%/4mm.
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1 Introduction and Background 
1.1 Statement of Problem 
1.1.1 General Problem 
Proton therapy has been used to treat cancer for more than 50 years, and over the past 
decade, its use has grown rapidly. At present, 23 proton centers are in operation in the United 
States and another 13 centers are in development [1]. As a consequence of the increasing 
interest in the use of protons, the demand for good quality assurance (QA) programs to control 
and maintain the standard of quality of patient care is high. Even though each particular proton  
therapy facility already has its own set of comprehensive quality assurance tests in place, 
based on the recommendations from the International Commission on Radiation Units and 
Measurements (ICRU) [2], an independent QA program that confirms accuracy, 
comparability and consistency of proton therapy delivery between facilities is also needed, 
especially for clinical trial activities. 
As a core support for its clinical trials, the National Cancer Institute (NCI) funds 
various quality assurance centers across the country in order to provide trial support and to 
help assure that institutions are delivering comparable and consistent doses of radiation. The 
Imaging and Radiation Oncology Core (IROC) Houston QA Center, formerly known as the 
Radiological Physics Center (RPC) [3], is one of those QA centers and has as a mission to 
assure NCI that participating institutions have acceptable quality assurance procedures and no 
significant systematic dosimetry inconsistencies, so that each site can be considered qualified 
and capable of providing quality clinical treatments for cancer patients. This is especially true 
for clinical trials that allow proton therapy since it is a relatively new mainstream form of 
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radiation therapy. In fact, the NCI, in 2012, developed guidelines [4] for the use of proton 
therapy in NCI funded multi-institutional clinical trials. These guidelines specify an approval 
process that each new proton facility has to go through before being allowed to enter a proton 
treated patient onto NCI clinical trials. In addition to the proton approval process, the 
guidelines also describe the use of protocol specific credentialing requirements. IROC 
Houston’s proton therapy approval process consists of completing a facility questionnaire, 
irradiating baseline anthropomorphic QA phantoms, consistent treatment of at least 3 
anatomic sites at the facility, annual remote monitoring of the proton beam outputs and an on-
site dosimetry reviews by an IROC physicist. IROC Houston also conducts a variety of 
credentialing activities, such as; protocol specific questionnaires to evaluate an institution's 
understanding of the protocol and their capabilities, treatment-planning standards to allow the 
institution to demonstrate their planning ability, and protocol specific use of anthropomorphic 
phantoms in order to verify the end to end process from imaging to treatment planning to setup 
to dose delivery for the specific treatment conditions of the protocol [5]. These mailable 
anthropomorphic QA phantoms used for the approval and credentialing processes are an 
important part of the remote monitoring audits and are used to verify the accuracy of the dose 
delivery for the individual proton treatments as they represent a hypothetical and/or patient 
treatment. These patient treatment verifications typically measure the precision of the dose 
delivered as well as the spatial distribution of the dose. The use of thermoluminescent 
dosimeters (TLDs) for point-dose measurements and radiochromic film for relative-dose 
distributions allows IROC Houston to measure the dose distribution delivered to the phantom 
that can then be compared to the dosimetry data calculated by the proton institutions to verify 
the accuracy of the planned proton treatment [6].  
15 
 
1.1.2 Specific Problem 
The NCI guidelines for the use of proton therapy in its clinical trials outline a 
credentialing process for the participating proton institutions that requires the use of 
anthropomorphic phantoms in order to mimic patient radiation treatment plans. With the 
recent increase in the use of Intensity Modulated Proton Therapy (IMPT) and as targets 
become more complex, the IROC Houston QA Center has developed a need to remotely 
evaluate the planning and dose delivery of these treatments as part of trial credentialing. In 
order to test the system’s ability to deliver a conformal dose to a target, and avoid dose to 
surrounding critical structures the IROC Houston has developed and used ten different 
heterogeneous, anthropomorphic phantoms that are used for clinical trial credentialing. The 
phantoms that have been previously designed and intended to be easily mailed to the 
institutions as an end to end QA monitoring include a stereotactic radiosurgery head phantom, 
a proton head phantom, an IMRT head-and-neck (H&N) phantom, a photon spine phantom, a 
proton spine phantom, a photon lung phantom, a proton lung phantom, a photon liver 
phantom, a proton liver phantom and a photon/proton pelvic-prostate phantom [3]. At this 
time, IROC Houston does not have an anthropomorphic QA H&N phantom that can be used 
to credential IMPT treatments for an oropharynx clinical trial comparing IMPT to IMRT that 
will soon be included in the NCI’s clinical trial portfolio. 
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1.2 Head and Neck Cancer 
Cancers of the oral cavity and oropharynx, which include the cancers of the lip, tongue 
and mouth, oropharynx, excluding the salivary glands and other pharyngeal sites, constitute a 
serious problem in the world. These anatomically related cancers, grouped together, represent 
the sixth most common cancers worldwide [7]. The yearly global incidence of oral cavity 
cancer is estimated to be approximately 263,000 cases, and the number of deaths from this 
cancer to be 127,000 [8]. In 2013, it was also estimated that 41,380 people were newly 
diagnosed and 7,890 died from these cancers in the United States [9]. 
Most of the cancers (>90%) of the oral cavity and oropharynx are squamous cell 
carcinomas (SCCs) [10]. Head and neck squamous cell carcinoma (HNSCC) is a term for 
squamous cell cancers that include the oral cavity, nasal cavity, the paranasal sinuses, the 
pharynx and the larynx. The oral cavity commonly includes the lips, anterior two thirds of the 
tongue, gingiva, hard palate, buccal and labial mucosa, retromolar pad, and floor of the mouth. 
The pharynx is considered to begin behind the nose and extend to the top of the trachea and 
esophagus (about 5 inches long), and is divided into three sections: nasopharynx, 
hypopharynx, and oropharynx, where the term “oropharynx” referrers to the posterior one 
third of the tongue, soft palate, palatine and lingual tonsils, and the posterior pharyngeal wall 
[11]. The anatomical sites and sizes of these malignancies will greatly influence the associated 
risk factors and the possible treatment options [12, 13]. 
Head and neck malignancies account for about 10% of all the cancers around the 
world, with roughly 40% of these cancers occurring in the oral cavity, 25% in the larynx, 15% 
in the pharynx, and the rest in the remaining sites (salivary glands, thyroid) [14]. The exact 
causes of these carcinomas are not sufficiently understood. Nevertheless, head and neck 
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cancers have been strongly correlated with alcohol and tobacco abuse, where each factor alone 
may account for a two- to three-fold increase in risk [15-17]. Even though tobacco and alcohol 
consumption are said to be the main aetiological factors, other risk factors have also been 
correlated with the disease. Viral agents, such as Epstein–Barr Virus (EBV) and the human 
papilloma virus (HPV) [18-20], dietary deficiencies or imbalances [21-23], dental health [24, 
25], occupation [26-28], and genetic and familial factors [29, 30] have been suggested to not 
necessarily be the cause of these malignancies but to be associated, individually or in 
combination, with an increased probability of the occurrence of these cancers. 
According to the International Agency for Research on Cancer (IARC), around 60 to 
80% of these malignancies could be prevented by monitoring the established risk factors [31]. 
Specifics that can be used as predictors of survival are reported to be tumor size, tumor stage, 
nodal status, grade of tumor, performance status, site of primary, thickness, depth of invasion, 
tumor margin, etc [13]. Prognosis is highly dependent on the local invasion and lymph node 
involvement. The 5 year survival rate is approximately 50% when lymph nodes are not 
involved, and falls to 30% in the case of lymph node involvement [14]. By the time a diagnosis 
is made, more than 40% of the patients have one or more metastatic sites, sometimes due to 
the first observable symptoms being minimal or even to being minimized by the patient or 
physician. Pain does not necessary start early, which results on more than 50% of the tumors 
to being detected at an advanced stage [14]. 
Currently, concurrent radiation therapy and chemotherapy is considered the standard 
of care for most of the patients with advanced head and neck malignancies [32, 33]. These 
advanced head and neck cancers require the delivery of reasonably high doses to the planning 
target volume. Due to the presence of large tissue heterogeneities, the large extension of the 
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treatment region, the variety of anatomical shapes and position of targets and organs at risk, 
planning treatments is one of the most complex tasks of conventional radiotherapy. Proton 
therapy, specifically IMPT, is now being considered to be a viable therapeutic option for 
patients with H&N cancers due to their dosimetry characteristics, as described below, that can 
limit damage to surrounding normal tissues.  
 
1.3 Protons in Radiation Therapy 
1.3.1 Background 
The idea of using energetic protons in medical treatments was first proposed by 
physicist Robert R. Wilson, Ph.D, in 1946. The use of proton radiation to treat patients was 
first attempted in the 1950s, however applications were restricted to limited areas of the body. 
In the late 1970s, with the development of newer technologies and improved accelerators, 
proton therapy was made more viable for medical applications, such as cancer treatment [34]. 
Similarly to photons, protons used in radiation therapy cause damage to the DNA of 
cells and ultimately can lead to cell death. As protons travel through tissue, they interact with 
atomic electrons and nuclei in the medium through Coulomb forces. These interactions will 
often produce ionizations and consequently result in absorbed dose. The deposition of energy 
through the medium, or dose, is described by the proton beam stopping power. The stopping 
power is dependent on the energy of the proton beam and on the properties of the medium it 
transverses through. Hence, the stopping power refers to the energy lost per unit path length 
of the material and is given by Equation 1 [35, 36]. 
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܁ሺ۳ሻ ൌ 	 ܌۳܌ܠ     Equation 1 
Where S is the linear stopping power which is a function of energy (E), and dE is the 
mean energy lost as the proton transverses a distance dx, typically given in MeV/cm. 
In order to obtain the stopping power that is independent of the density of the material 
the equation above can be normalized by the density of the absorbing medium, and is 
expressed in Equation 2: [35, 36] 
܁ሺ۳ሻ ૉൗ ൌ ૚ૉ	
܌۳
܌ܠ     Equation 2 
Where SሺEሻ ρൗ  is the mass stopping power and ρ is the density of the material, given 
in MeV-cm2/g. 
The average distance the proton travels before coming to complete stop, called the 
particle range, can simply by obtained by integrating the stopping power formula above and 
is shown in Equation 3: [35, 36] 
܀ ൌ	∮ ૚	܁ሺ۳ሻ
۳૙
૙ ܌۳    Equation 3 
Where R is the range, S(E) is the linear stopping power and E଴ is the initial kinetic 
energy of the proton, thus given in g/cm2.  
The correct prediction of the position in which the protons will stop is crucial for a 
precise treatment. The accuracy in proton therapy treatment planning strongly depends on the 
precision of the stopping power information of the tissues in the patient’s body so that the 
deposition of the dose is mainly focused in the target, with the sparing of the healthy 
surrounding critical structures [37]. 
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1.3.2 Formation of the Proton Beam 
Protons are required to be accelerated to very high energies (160 to 250 MeV) in order 
to be suitable for medical purposes. There are 3 types of proton accelerators: linear 
accelerators, cyclotrons and synchrotrons. However, because of the need of protons to be 
accelerated to very high energies in the clinic, conventional linear accelerators are not 
appropriate for radiotherapy. In order to achieve those energies, linear accelerators would be 
required to occupy a large space and therefore are not preferred in radiation therapy. Even 
though new technologies such as laser plasma particle and high-gradient electrostatic 
accelerators are being developed, cyclotrons and synchrotrons are currently the main 
accelerators used in proton beam therapy [35]. 
1.3.2.1 Cyclotrons 
In a cyclotron, positively charged particles, such as protons and deuterons, are injected 
into the center of a round chamber. An electric field is applied at certain parts of the chamber, 
accelerating the particles and increasing their velocity. They are forced to travel in a circular 
motion due to the application of magnetic fields. With the increase in speed from the electric 
fields, the radius of the particles increases and can then be controlled by the magnetic fields 
along the chamber, until they exit with relatively low energies. The proton energies are limited 
because they achieve relativistic speeds, where additional acceleration causes the particle to 
gain mass and change their rotational period. A simplified diagram of a cyclotron is shown in 
Figure 1.1. 
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Figure 1-1: Diagram of a Cyclotron 
Taken from: https://trac.cc.jyu.fi/projects/ohj1s13/wiki/suunnitelmat/joautant 
Synchrocyclotrons and isochronous cyclotrons, on the other hand, can compensate for 
the increase in particle mass and accelerate particles to much higher energies. 
Synchrocyclotrons allow for adjustments in the frequency so that the proton’s orbital motion 
still resonates with the electric field and isochronous cyclotrons increase the magnetic field 
with radius in order to keep a constant cyclotron frequency with energy, allowing for much 
higher speeds to be obtained (250 MeV). The high energy proton beams can then be modulated 
to treat at any depth with the use of energy degraders [35]. 
1.3.2.2 Synchrotrons 
The University of Texas MD Anderson Cancer Center Proton Therapy Center in 
Houston (PTC-H) uses a synchrotron (70 – 250 MeV) to produce their proton beam [38]. 
Synchrotrons accelerate the particles by injecting low energy protons (3 to 7 MeV) into a 
narrow vacuum tube ring, where they are accelerated periodically with the use of 
radiofrequency (RF) cavities. Bending magnets keep the charged particles in the circular orbit. 
The RF frequency and the magnets strengths’ are adapted as the protons’ energy is increased, 
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until the desired beam is obtained, and can then be extracted. A schematic of a synchrotron 
accelerator can be seen in Figure 1.2. 
 
Figure 1-2: Diagram of a Synchrotron 
Taken from: http://kids.britannica.com/comptons/art-124574/Particles-are-injected-into-the-ring-of-
an-alternating-gradient 
In contrast to cyclotrons, synchrotrons can accelerate the particles to the precise 
energies needed for radiation therapy. That advantage allows for the production of beams that 
can treat at any depth without the need for energy degraders, which produce greater neutron 
contamination, create higher post treatment radioactivity and require more shielding [35]. 
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1.3.3 Proton Therapy Treatment Modalities 
1.3.3.1 Passive Scattering 
The simplest way of spreading a near-monoenergetic proton beam to a useful field size 
is by using a high atomic number scattering foil, similar to linear accelerators for electron 
treatments. These passive scattering systems require the use of custom blocks, usually made 
with brass or cerrobend, range compensators and range modulators. Figure 1.3 shows an 
example of the custom blocking used to shape the desired treatment field. Range compensators 
on the other hand, made with low atomic number materials, are used to compensate for patient 
surface irregularity, PTV surfaces and tissue heterogeneity, and are shown in Figure 1.4. 
Finally, range modulators are necessary to spread the Bragg peak in depth so that the entire 
PTV thickness is covered (SOBP), shown in Figure 1.5. 
 
Figure 1-3: Passive scattering brass aperture for cranial blocking 
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Figure 1-4: Acrylic passive scattering range compensators 
 
Figure 1-5: Passive scattering range modulators 
One area of concern in passive scattering systems is stray radiation. Unwanted dose 
delivered to healthy tissues is produced both within the patient himself, which is unavoidable 
regardless of the treatment method, and in the structural components of the accelerator. 
Passively scattered proton therapy (PSPT) contributes with a non-negligible amount of 
neutron dose to the patient that leaks out of the treatment head [39]. Neutrons have an 
enhanced RBE compared to protons [40], and even reasonably small doses increase the risk 
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of secondary cancers [41]. Leakage neutron dose delivered to patients can be reduced by 
using scanning beams instead of passively scattered beams [42]. 
1.3.3.2 Pencil Beam Scanning 
Pencil beam scanning, also known as spot scanning, magnetically scans a narrow beam 
of protons placing the Bragg peaks within the voxels of a three dimensional grid. There have 
been studies that suggest that spot-scanned proton beams offer the most advantageous 
therapeutic ratio over scattered proton beams [43]. This method generates treatment fields of 
any size and shape without the use of custom designed apertures, scattering foils or physical 
range compensators [35]. This is an advantage because it decreases the degradation of the 
beam energy, loss of treatment range and the neutron contamination discussed in the previous 
section, 1.3.3.1. Therefore, treatment plans control the delivery of dose simply as a function 
of beam intensity, depth, field size, beam positioning, and direction, which can be fully 
optimized with the use of intensity-modulated proton therapy (IMPT) [35]. 
Intensity-modulated proton therapy, analogous to IMRT for photon therapy, allows 
for greater dosimetric optimization and for better sparing of adjacent organs at risk (OARs) 
[44]. The modality uses multiple ports with inhomogeneous proton fluence so that, when 
combined, they deliver a homogeneous dose distribution to the target, keeping the dose to the 
surrounding normal tissues acceptable. Both conventional and IMPT techniques are precise 
and efficient modes of proton beam delivery with the method of pencil beam scanning [35]. 
Protons offer a variety of advantages over photons. The use of protons in radiation 
therapy has become very popular because of its superior dose distribution characteristics that 
allows for high doses to be delivered to targets and lower doses to be delivered to surrounding 
healthy tissues distal to the target, potentially resulting in increased tumor control and lower 
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normal tissue toxicities. When compared to photons, protons scatter less in the patient due to 
their smaller scattering angles, as consequence of their heavier masses. Another key advantage 
of protons is the steep dose fall-off at the end of their range. The dose depth distribution for a 
proton beam is characterized by the phenomenon known as the Bragg peak. This property of 
proton beams in tissue, where they quickly stop after the Bragg peak, brings the obvious 
advantage of not depositing any exit dose beyond a certain depth [35]. Figure 1.6 shows the 
depth dose distribution of a monoenergetic proton beam in comparison to a photon depth 
distribution. 
 
Figure 1-6: Depth dose distribution of a monoenergetic proton beam in 
comparison to a photon depth distribution 
Taken from: http://www.p-cure.com/Why_Proton_Overivew.html 
As it can be seen in Figure 1.6, the monoenergetic proton beam cannot cover the full 
extent of most tumors. The Bragg Peak phenomenon is a function of the energy of the each 
beam and by varying the energy of a proton beam with a range modulator or at the 
synchrotron, a compilation of pristine Bragg Peaks can be created to form what is known as 
the Spread Out Bragg peak (SOBP), shown in Figure 1.7.  
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Figure 1-7: Compilation of pristine Bragg Peaks forming the Spread Out Bragg 
peak (SOBP) to cover the target 
Taken from: http://archive.ahrq.gov/news/events/conference/2010/trikalinos/index.html 
The spread out Bragg peak is originated by the superposition of different 
monoenergetic beams, and it allows for a better coverage of larger targets. Despite the 
advantages, one concern with the use of SOBP beams is that the entrance dose in the medium 
is significantly increased. 
1.3.4 Relative Biological Effectiveness 
Protons also show radiobiological advantages when compared to photons or electrons. 
The relative biological effectiveness (RBE) represents an assessment of the damage caused 
by the different types of radiation. This RBE comparison is established by dividing the dose 
of a given reference type of radiation, typically Cobalt-60 or 250 kVp x-rays, by the dose 
delivered by any type of radiation in order to obtain the same biological effect, shown in 
Equation 4 [35]: 
܀۰۳ ൌ 	۲ܗܛ܍	ܚ܍܎܍ܚ܍ܖ܋܍	ܚ܉܌ܑ܉ܜܑܗܖ	۲ܗܛ܍	ܜ܍ܛܜ	ܚ܉܌ܑ܉ܜܑܗܖ    Equation 4 
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Relative biological effectiveness depends on the type and quality of the radiation, the 
actual biological endpoint considered, dose fractionation, and most significantly, the linear 
energy transfer (LET) of the radiation. In general, RBE increases with LET, and because 
charged particles have a higher LET, they also have a higher RBE. On the same note, the LET 
of a charged particle increases as the particle slows down, and thus, the RBE is greater in the 
Bragg peak region [35]. The proton radiation therapy community has adopted an average RBE 
value for protons to be 1.1. Paganetti [45] presented data for a large number of proton 
biological studies and compiled all of the calculated proton RBEs resulting in the average 
value of 1.1. In essence, this means that the final biological endpoint produced by protons can 
be the same as photons, but with 10% lower proton physical dose [35]. 
1.4 Dose Uncertainties in Proton Therapy 
The main advantage of proton therapy treatments comes from the concept that the 
integral dose deposited on a patient for a given tumor is always lower than when compared to 
other modalities, mostly due to the lower exit dose. However, the great potential of proton 
therapy can only be optimized if the range of these protons can be predicted accurately when 
generating a treatment plan [46]. The range in tissue can be affected by uncertainties existent 
in the treatment plans such as, patient set up, imaging, beam delivery, dose calculations, organ 
motion, anatomical variations, or other biological considerations [46]. Poor calculations of the 
particle’s physical range can translate to erroneous treatments that could overdose the healthy 
tissues or even under dose the tumor. In order to account for these potential deviations, MD 
Anderson Proton Therapy Center in Houston applies a correction in the proton beam range of 
2.5% of the range plus an additional 2 mm for H&N sites.  
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With the increase in interest in proton therapy and with the many opportunities for 
inaccuracies in treatment delivery, the need for a QA program that can evaluate these 
treatments is evident. The phantom created for this project was designed to simulate a human 
head and neck. However, some of the inherent complexities and uncertainties of the human 
body that occur in real patients are not present in the phantom, for instance, organ motion and 
anatomical variations through the course of treatment. 
 
1.5 Hypothesis 
An anthropomorphic H&N phantom can be designed and built to evaluate proton 
therapy H&N treatment procedures that can reproducibly (±3%) assure agreement between 
the measured doses and calculated doses to within ±7%/4mm. In order to verify the 
hypothesis, the following aims were established for this project: 
1.     Design an anthropomorphic H&N phantom that can mimic human structures and 
disease with tissue equivalent materials for an oropharyngeal cancer. 
2.     Image the H&N phantom with CT and create clinically relevant treatment plans 
for passive scattering and spot scanning. 
3.    Irradiate the phantom 3 times with each treatment plan created and measure the 
delivered dose distribution and the dose to specific points (targets and normal tissues) within 
the phantom. 
4.    Compare the measured and calculated proton doses and distributions to determine 
agreement and precision. 
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1.6 Research Approach 
Methodology: 
1.     The phantom will be designed based on the composition, size and geometry of a 
generalized head and neck tumor (oropharyngeal) and critical structures, such as the parotids 
and the spinal cord. 
2.     CT images will be obtained for the phantom and two treatment plans (passive 
scatter and spot scanning) will be developed using the Eclipse proton planning system. The 
plan, approved by a radiation oncologist, will be developed based on typical clinical 
constraints for a generalized H&N cancer adopted at the Proton Therapy Center – Houston. 
3.     Radiochromic film and TLD capsules will be placed in the phantom through a 
cylindrical insert. The phantom will be irradiated 3 separate times for each approved treatment 
plan in order to evaluate the reproducibility of the phantom design. 
4.     The 2D dose distributions and specific point doses determined from the film and 
TLDs will be compared with the planning system calculated values, dose profiles and dose 
distributions to determine the agreement and reproducibility. 
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2 Materials and Methods 
2.1 The Anthropomorphic Head and Neck Phantom 
2.1.1 Phantom Design Considerations 
In order to remotely evaluate the planning and dose delivery of these treatments, IROC 
Houston has creatively designed and built a number of different heterogeneous mailable 
anthropomorphic QA phantoms. One aspect that all of these phantoms have in common is that 
they all try to simulate the true human anatomy in some way. Some of the phantoms consist 
simply of plastics shells that can be filled with water, and others can be more complex, 
mimicking the lung motion of an actual patient. One important characteristic of the design is 
to include tissue heterogeneities in order to properly account for the clinically relevant 
anatomical heterogeneities and to be able to image different structures (targets vs. critical 
structures). Another important consideration for this project is the human anatomy typically 
involved in head and neck malignancies. The complexity of head and neck cancer is due not 
only to the large extent and involvement of typical malignancies, but also to the large number 
of critical structures surrounding or adjacent to the target, such as, the parotid glands, oral 
cavity, esophagus, larynx, mandible and teeth, eyes and spinal cord. Therefore, in order for 
radiation treatments to be successful, not only do the prescribed target doses need to be 
delivered uniformly throughout the tumor but also critical structures constraints need to be 
respected. Typical dose-volume constraints used at MD Anderson Cancer Center for proton 
therapy treatments are shown in Table 1. 
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OAR Dose Volume 
Parotids 26 Gy Mean 
Cord 45 Gy Max 
Mandible 70 Gy Max 
Cochlea 35 Gy Max 
Lens 5 Gy Max 
Larynx 25 Gy Mean 
Brainstem 45 Gy Max 
Esophagus 25 Gy Mean 
Table 1: Dose-volume constraints used in typical head and neck proton 
treatments 
 
2.1.2 Determination of Tissue Equivalent Materials for Proton Therapy 
IROC Houston currently has a variety of anthropomorphic phantoms that are used in 
their remote auditing QA programs, including a Head and Neck photon phantom. However, 
the need for the construction of a proton Head and Neck phantom can be justified based on 
the requirement for these materials to be tissue equivalent for proton therapy. Materials that 
can be considered tissue equivalent for photon beams may not necessary be tissue equivalent 
for proton beams. The relative linear stopping power (RLSP) should be used in order to 
determine the tissue equivalency of materials to be exposed to proton beams, as the electron 
density information is used for photons. Proton treatment planning systems rely on the 
relationship between Hounsfield units and RLSP instead of electron density [47]. Figure 2.1 
shows the curve, RLSP versus Hounsfield units, used to determine proton equivalent 
materials. 
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Figure 2-1: Relative Linear Stopping Power versus Hounsfield Units curve used 
to determine proton equivalent materials 
Materials that lay on the curve in Figure 2.1 are considered proton tissue equivalent 
materials, where a percent difference of less than 5% in the RLSP is the cutoff for materials 
suitable for proton therapy [47]. For instance, blue water and solid water are materials that 
will behave like human tissue when exposed to a proton beam, while acrylic, a photon 
equivalent material, will not.  
One interesting note related to the first insert design is that polyethylene and blue water 
were used as the materials for the target and critical structures. However, according to recent 
literature, polyethylene demonstrates slight variations in stopping power for different proton 
treatment energies [48]. As a result, the final composition of the cylinder was solid water and 
blue water for the structures inside. The evident need for different materials was justified in 
order to allow for a clear visualization of the structures in the CT scans, and consequently the 
success of the proton treatment planning. 
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2.2 Image Acquisition 
The phantom was scanned with the MD Anderson Proton Therapy Center of Houston’s 
CT scanner, a GE LightSpeed RT16. A typical head and neck protocol was used to image the 
phantom, with 1.25 mm slices at 120 kVp. In addition, the scan was done in helical mode with 
a pitch of 0.9375. 
In order to assure reproducibility, the phantom was placed in the supine position, on a 
KlarityTM mold that was shaped to the Head & Neck phantom. The mold also guaranteed that 
air gaps were minimized in the scan. Small pieces of tape with cross marks were place on the 
sides, forehead and neck of the phantom, in the interest of using the room lasers to follow the 
correct alignment during treatment setups. Actual patients require other features in order to 
guarantee precise setup up, such as Head & Neck masks, specialized head rests and bite 
blocks. However, due to the inanimate nature of the phantom, those did not need to be 
employed. Figure 2.2 shows the phantom resting on the KlarityTM mold with the laser tags 
taped on the surface. 
 
Figure 2-2: Head & Neck phantom resting on Klarity mold with laser tags taped 
on the surface 
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2.3 Treatment Planning 
Treatment planning considerations were made following the recommendations of the 
MD Anderson Proton Therapy Center (PTC) of Houston. The typical Head and Neck dose 
prescription employed at the PTC is delivered in dose gradients, with the goal of hitting the 
target while minimizing the dose to the surrounding healthy tissue. For this research study, 
the gross target volume (GTV) was considered to be the clinical tumor volume (CTV), 
however that is not clinically implemented since the extent of the microscopic disease is not 
exactly known. Standard guidelines used at the PTC aim to deliver the prescription in 33 
fractions as following; 70 Gy to the primary target, 63 Gy to high risk lymph nodes and 57 
Gy to additional risk nodal areas. Optimal plans are usually achieved with the use of posterior 
beams and/or anterior oblique ones. One main reason why these are popular beam 
arrangements options is because of the large number of critical structures in the anterior part 
of the head and neck region, such as mandible, teeth, tongue and eyes.  Another particularly 
relevant reason is related to the oral and nasal cavities. These areas will not only change the 
range of the proton beam due to the absence of actual tissue, but will also transform during 
the course of treatment, filling and empting with nasal mucus.  
The CT scan was performed on a regular couch, which as a consequence, required the 
insertion of a digital couch into the treatment planning system, in order to account correctly 
for the posterior proton beam ranges. Another necessary step for the correct calculation of the 
proton ranges was the CT number override of the imaging artifacts caused by the pin pricks 
and screws present in the insert. The artifact areas were also contoured and given the real 
tissue-like (solid water, in the case of the cylinder) Hounsfield unit number. 
36 
 
Although typical treatment doses for Head and Neck cancer are on the order of 70 Gy, 
the IROC protocol requires the prescription to be a factor of approximately 10 times smaller. 
Consequently, the primary CTV was planned to have 6 Gy delivered in one fraction. The 
reason behind lowering of the dose delivered is related to the fact that the total absorbed dose 
affects the film response to ionizing radiation. IROC uses Gafchromic EBT2 film and it 
saturates at doses of around 10 Gy [49]. 
The treatment plan was generated with the assistance of a dosimetrist and an 
experienced medical physicist member of my committee. The plan was based on typical 
clinical dose constraints of 26 Gy for the parotids and 45 Gy to the spinal cord. However, it is 
important to note that these constraints were also scaled according to the target dose and were 
accepted to be 2.6 Gy and 4.5 Gy respectively. 
 
2.3.1 Spot Scanning Treatment Plan 
A spot scanning treatment plan was generated for the target using the prescribed dose 
of 6 Gy normalized to 100% of the PTV. The optimal dose coverage with best tissue sparing 
was achieved with the use of one posterior beam, and two anterior oblique ones. Additional 
plan parameters employed are listed in Table 2. Figure 2.3 and Figure 2.4 show screenshots 
of axial and sagittal slices of the treatment isodose lines respectively. Figure 2.5 shows the 
Dose volume histogram (DVH) of the spot scanning plan.  
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Spot Scanning Treatment Plan Parameters 
Prescription: 6 Gy 
  Beams 
  Posterior Anterior Left Anterior Right 
Gantry Angle [deg] 180 65 295 
Couch Angle [deg] 0 340 20 
Field Weight 1 1 1 
MU 135.94  131.90  114.45 
Table 2: Spot scanning treatment plan parameters 
 
 
Figure 2-3: Spot scanning treatment plan shown in the axial plane 
 
38 
 
 
Figure 2-4: Spot scanning treatment plan shown in the sagittal plane 
 
Figure 2-5: DVH of spot scanning beam treatment plan with PTV, cord and 
parotids 
According to the plan, the PTV would receive adequate dose coverage where 96.7% 
of the volume would be given 100% of the dose. The parotids were under the acceptable dose 
constrains. The mean dose delivered to the left and right parotids were, 2.59 Gy and 2.30 Gy 
39 
 
respectively, meeting the 2.6 Gy limitation. The cord received a mean dose of 3.77 Gy but a 
maximum dose of 5.7 Gy, which exceeded the 4.5 Gy maximum dose restriction. This 
compromise had to occur because of the unrealistic anatomic fit of the structures in the insert. 
In normal human anatomy, the parotids and cord are more superficial than the phantom insert 
allowed for. The insert could not have been wider because it had to fit though the neck while 
still allowing for enough material to support the head. Therefore, a higher than clinically 
advisable dose was delivered to the cord in order to maintain target coverage. 
2.3.2 Passive Scatter Treatment Plan 
A passive scattering treatment plan was generated with two AP PA beams with the 
efforts of achieving tumor control. Figure 2.6 shows a 3D view of the proton beams and the 
custom 6 cm thick brass blocks designed. The brass blocks were designed to fit to the target 
structure and were edited to provide some shielding to the parotids as seen in Figure 2.7. Plexi 
glass compensators were also added to the plan in order to account for patient irregularities, 
PTV surfaces and tissue heterogeneity.   
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Figure 2-6: 3D view of the AP PA proton beams through brass blocks 
 
Figure 2-7: Beam’s eye view of the brass block fit to target structure with 
indentations protecting parotids 
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The passive scattering plan offered great sparing of the parotids but unreasonably high 
doses to the cord. In addition, the target coverage was insufficient, offering numerous hotspots 
and poor uniformity, as it can be seen in Figure 2.8 and Figure 2.9. In the axial view, it is 
possible to notice how the 100% isodose line is not well conformed to the target presenting 
high tissue toxicity to the surroundings tissues, as well as the OARs designed in the phantom. 
It is also apparent in the axial image that there is a large area of the tumor that is not covered 
by the 100% isodose line, leaving great portion of the GTV under dosed. 
 
Figure 2-8: Axial view of isodose lines of passive scattering plan 
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Figure 2-9: Sagittal view of isodose lines of passive scattering plan 
The impracticality of the plan can be analyzed further through the DVH created by the 
TPS in Figure 2.10. The parotids were both well under the dose constraints considered for the 
plan, 0.76 Gy for the left and 0.96 Gy for the right parotid. However the cord got a maximum 
dose that was equivalent to the total prescribed target dose of 6.02 Gy. Aside from the 
enormous cord toxicity, it is possible to confirm again though the DVH that not all of the 
target was covered and there were a large number of hotspots, totaling the maximum target 
dose to 6.78 Gy. 
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Figure 2-10: DVH of passive scattering beam treatment plan with PTV, cord 
and parotids 
 
2.4 Treatment Delivery  
All irradiations trials were performed on the G3 spot scanning beam gantry at the PTC-
H. The phantom was placed in the supine position and aligned with the gantry lasers and x-
ray imaging. The AP and lateral kV images were then compared with the DRRs generated in 
the TPS. The imaging parameters used for the setup were the same as the ones recommended 
for head and neck patients treated at the PTC and are shown in Table 3. 
Orientation AP Lateral 
kVp 60 70 
mA 320 400 
ms 50 63 
Table 3: Imaging parameters used in the alignment 
Once one complete treatment was delivered to the phantom, dosimeters were unloaded 
and new unirradiated TLDs and film were reloaded. A new set of x-rays were acquired before 
the subsequent trials in order to ascertain the best positioning. Figure 2.11 shows the three 
different positions of the gantry for the beams used to deliver the treatment. 
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Figure 2-11: From left to right; posterior beam, right oblique beam and left 
oblique beam 
2.5 Dosimetry 
2.5.1 Planar Dosimetry 
2.5.1.1 Film 
Gafchromic EBT2 film (Ashland , Wayne, New Jersey), was used in order to perform 
the analysis of the sagittal and axial dose distributions of the irradiations. Radiochromic film 
was considered the appropriate relative dosimeter for the study of the dose profiles due to the 
fact that it shows no angular dependence, is near tissue equivalent and IROC-H has the 
infrastructure to analyze it precisely and accurately. In addition, it offers sensitivity (0.1 to 10 
Gy) in the required range for this project (6 Gy), and has great spatial resolution. It can also 
be handled in visible light and is self-developing [49, 50], making this passive detector very 
suitable for the remote quality programs established at IROC. EBT2 films from lot number 
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08131501 and an expiration date of August 2017 were used for this study. Figure 2.12 shows 
the cross section of the Gafchromic EBT2 components [51]. 
 
Figure 2-12: Diagram of cross section of the Gafchromic EBT2 components 
2.5.1.2 Film Calibration 
A film calibration needs to be established to determine the accurate relationship 
between the intensity of the film and the dose delivered. The same procedure was performed 
using a passive scatter irradiation technique at the PTC-H for all the irradiated film. A medium 
size aperture block was used. At 160 MeV, the SOBP was 10 cm and therefore required 8 cm 
of acrylic buildup above and below the film. The center of the film was set at 270 cm source 
to axis distance (SAD). The film was cut into sections of 5 x 10 cm2 and the MU used for each 
dose level was calculated using Equation 5 and can be seen in Table 4. The range shift factor 
and the SOBP output factor was 1 for the 10 cm SOBP, while the relative output factor was 
given to be 0.792. 
Equation 5 
ܯܷ	 ൌ 	݄ܲݕݏ݈݅ܿܽ	ܦ݋ݏܴ݈݁݁ܽݐ݅ݒ݁	ܱݑݐ݌ݑݐ	ܨܽܿݐ݋ݎ ∗ ܱܵܤܲ	ܱݑݐ݌ݑݐ	ܨܽܿݐ݋ݎ ∗ ܴܽ݊݃݁	݄݂ܵ݅ݐ	ܨܽܿݐ݋ݎ	 
~ 0.28 mm
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Dose (Gy) MU 
0.5 62.73 
1 126.2 
2 252.5 
3 378.7 
4 505 
5 631.3 
6 757.5 
7 883.8 
8 1010.1 
Table 4: MU required for each dose used in film calibration 
The doses shown above are physical doses and therefore did not take into account the 
proton RBE. The RBE was not taken into account in these MU calculations because the dose 
distribution analyzed later in the film was normalized to the TLD doses, which involved the 
1.1 correction. 
The film was scanned using a SBIG CCD Camera, model STF 8300M. The dose 
versus intensity curve was plotted and a third degree polynomial was fit to it, shown in Figure 
2.13. The coefficients obtained from the fit were later inserted into the IROC software in order 
to proceed with the analysis and convert the film intensity to dose. To ensure the correct 
orientation for all the tests, the pieces of films were marked with reference points on the edges. 
The read out was performed at least 24 hours after the irradiations to allow the film to stabilize 
and assure accurate measurements [51]. 
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Figure 2-13: Film calibration curve and fitted equation for EBT2 lot 08131501 
for proton beam 
2.5.2 Point Dosimetry 
2.5.2.1 TLD 
Thermoluminescent dosimeters (TLDs) were used as point dosimeters in the phantom 
providing absolute dose measurements at the specific locations where they were positioned, 
such as target and OARs. TLDs are passive detectors made of LiF crystals filled with 
impurities that create imperfections in the lattice of the material, also called energy traps. Once 
irradiated, electrons from the ground state can receive sufficient energy to be raised to the 
conduction band and get trapped in crystal lattice. These electrons can be released through a 
heating process and emit visible light [35]. The amount of TL light emitted is proportional to 
the dose delivered, and can be finally detected with a photomultiplier tube. 
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TLDs carry a valuable set of advantages in this project because they display a wide 
useful linear dose range (10E-5 – 10 Gy), and are dose rate independent [35]. In addition, 
TLDs are also small in size, not disturbing the radiation field, and are accurate and reusable. 
One important consideration is that TLDs require an annealing process in order to remove 
residual radiation. The detector response is affected by the previous radiation and heating 
history. Therefore a standard annealing process needs to be completed before the subsequent 
irradiation. This standard procedure is well known by IROC and was applied to assure reliable 
collection of measurements.  
There are several necessary parameters in order to calculate the final dose delivered to 
a powder TLD and they are shown in Equation 6. The first term in represents the 
thermoluminescent signal per unit mass, ܥ஽,௪ is calibration factor, ݇ி is the fading correction, 
݇ா	is the energy correction (unity for proton beams) and ݇௅ is the linearity correction.  
ࡰ ൌ	ࡹ࢘ࢇ࢝ ∗ ࡯ࡰ,࢝ ∗ ࢑ࡲ ∗ ࢑ࡱ 	∗ ࢑ࡸ   Equation 6 
The M reading is normalized by the powder mass so that any mass differences between 
the TLDs did not affect the calculation. The TL signal was given in nC and the powder mass 
in mg. Similar to ஽ܰ,௪ for ion chambers, the calibration factor ܥ஽,௪	is responsible for the 
conversion to dose, taking into account the different system sensitivity between the different 
TLD batches and any variation between readout sessions. The fading correction factor is 
necessary because trapped electrons will occasionally exit their excited states, resulting on the 
fading of the signal over time. The fading correction can be calculated using a double 
exponential modeled of the curve obtained from the readout percent signal versus time, and is 
shown in Equation 7: 
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࢑ࡲ ൌ ࡺࢇࢋష࢈࢚ାࢉࢋషࢊ࢚    Equation 7 
Where N, a, b, c, d are coefficients determined based on the TLD batch 
characterization performed by IROC and t is days from irradiation. For the lowest possible 
fading correction, the TLDs should be read a minimum of 14 days after the irradiation.  
A linear correction is also needed since TLD responses are not perfectly linear. 
Equation 8 is used by IROC to calculate the linear correction factor, where e and f are batch 
specific coefficients. 
࢑ࡸ ൌ ൫ࡹ࢘ࢇ࢝ ∗ ࡯ࡰ,࢝ ∗ ࢑ࡲ൯ ∗ ࢋ ൅ ࢌ   Equation 8 
One important aspect about the correction factors is that they all have to be established 
for a specific batch of TLDs, since they can all vary slightly between batches. Double loaded 
LiF TLD-100 dosimeters (Quantaflux, LLC, Dayton, OH) were used for each irradiation. The 
TLDs were read out 10 days after the irradiations and the physical dose obtained from them 
was multiplied by 1.1, the proton RBE, in order to obtain the equivalent absorbed dose. 
2.5.2.2 TLD Characterization 
TLD calibration is done by irradiating a set of standard dosimeters to a known dose of 
radiation and establishing the correction factors needed. The standards were irradiated to a 
known dose of 300 cGy by a 60Co machine. This characterization was done by the IROC prior 
to irradiation and the correction factors obtained are tabulated below. The standards used were 
of the same batch of TLD powder and therefore their previous calibration was valid to be used 
in this project.  
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Corrections 
Factors 
Value 
N 1.3493 
a 1.2815 
b 0.0001 
c 0.0678 
d 0.0719 
e -0.0003 
f 1.1005 
Table 5: Fading and Linearity Correction Factors 
2.6 Dosimetric Analysis 
2.6.1 CT, Film and TLD  
IROC Houston uses a software developed internally, RCPFilm, to register the CT 
images and dose distribution with the TLD and film locations. The phantom insert contained 
pin pricks of known locations that would prick the film once loaded. The pin pricks were used 
to spatially orient the film with respect to the planned CT data. This was done by using an 
isocenter located in the target in the axial cut of the insert and measuring the physical distances 
to the pins. These distances were then inserted in the program and used as a coordinate system. 
Similarly, TLD distances are also imputed into the program and used as a 3D reference system 
for the program to spatially orient the CT images.  
Once the film is correctly registered the calibration curve previously obtained is then 
applied to convert the film intensity values to dose. The TLD measurements obtained inside 
the target serve to scale the film dose. The TPS values are divided by the measured TLD 
values and that ratio is used to scale the final dose distribution obtained in the film. The reason 
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for this step is due to the fact that film only offers a relative dose measurement and therefore 
needs to be normalized by a reliable absolute dosimeter, such as TLDs. 
2.6.2 Gamma Analysis 
The agreement between the 2D dose distribution on the film and the one predicted by 
the TPS was analyzed using a gamma analysis procedure. The analysis can be performed by 
the same IROC in-house software using the properly registered film. Unwanted pixels are 
masked off and, therefore are not included in the analysis, such as pin pricks, pen marks and 
film gaps caused by the axial film. Figure 2.14 shows the sagittal film with the unwanted 
marks masked out. The IROC-H expects an 85% pixel passing rate for the gamma analysis; 
hence the same criterion was used for this study. 
 
Figure 2-14: Sagittal film with the unwanted marks masked out
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3 Results 
3.1 The Anthropomorphic Head and Neck Phantom 
3.1.1 Design and Construction 
The head and neck (H&N) phantom created in this project is composed of tissue 
equivalent materials with real human bone and air gaps in the beam path. More specifically, 
the original phantom purchased was an Alderson phantom from The Phantom Laboratory 
(NY) made of Alderson water equivalent plastic with designed airway channels and a human 
skull inside to mimic actual human head anatomy. Figure 3.1 shows the head phantom 
purchased and Figure 3.2 illustrates the sagittal and axial CT scan of the original phantom 
showing the oral and sinus air cavities and human skull previously mentioned. 
 
Figure 3-1: Alderson Head phantom 
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Figure 3-2: Sagittal and Axial CT scan of the original head phantom purchased 
prior to modifications 
To be an appropriate quality assurance phantom for proton trials the head phantom had 
to include imageable targets and critical structures that mimicked human anatomical 
dimensions and the usual extent of oropharyngeal disease, while still accommodating 
radiation dosimeters. In order to facilitate the analysis of the dose profile and dose distribution 
a cylindrical insert containing all the relevant structures and dosimeters was designed based 
on actual patient anatomy. The insert design included a “horse shoe” shaped target that 
wrapped partially around the spinal cord and placed in the center of the insert, along with three 
relevant organs at risk, the spinal cord and two parotids placed laterally. The placement of the 
structures were such that proton beams would have to travel through bony structures as well 
as air cavities. As mentioned previously, the parotid structures had to be placed deeper than 
usual human anatomy because of physical limitations of the phantom, but their placement was 
adequate so as to not be unrealistic and still represent an oropharyngeal treatment. Therefore, 
54 
 
the maximum diameter allowed for the insert was 9.5 cm approximately. Figure 3.3 illustrates 
the 3D schematics of the design and Figure 3.4 shows the dimensions of each structure, where 
the spinal cord is 13 cm long, the target is 8 cm long and each parotid 3.5 cm long. 
 
Figure 3-3: Schematics of the insert design 
 
Figure 3-4: Dimensions of Structure and Separations 
The insert was split into four pieces so that radiochromic film could be inserted in the 
axial and sagittal planes. In order to keep the pieces held tightly together and avoid any air 
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gaps, the four loose pieces of the insert are attached together using small 6-6 nylon screws 
and the whole cylinder is held secure by an external thin (2 mm) plastic sleeve made of 
polyethylene. The film is prevented from rotating or moving inside the phantom by small 
stainless steel pins that also serve to place registration marks on each film. Holes were created 
inside each relevant structure, one for each parotid and two for the target and spinal cord to 
hold TLD capsules, so that absolute dose measurements could be made in each structure. 
Figure 3.5 shows the insert that was constructed with and without the plastic sleeve and Figure 
3.6 shows the sagittal and axial view of the cylindrical insert with the superior target TLD in 
place. 
 
Figure 3-5: Insert with and without the sleeve cap 
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Figure 3-6: Sagittal and axial view of the cylinder insert 
3.2 Passive Scattering Considerations 
After multiple iterations, it was determined that a passive scattering treatment plan for 
an oropharyngeal proton treatment was clinically unrealistic and could not be delivered to the 
designed phantom. This was not surprising since the MD Anderson clinician developing the 
proton oropharyngeal clinical trial suspected that a viable clinical treatment could only be 
achieved using Intensity Modulated Proton Therapy (IMPT) with a pencil beam scanning 
technique. Yet an attempt to develop a passive scattering plan was made. It was determined 
that the structures (target, cord and parotids) chosen to be in the insert, based on actual patient 
anatomy, were too close together for the passive plan to successfully achieve the treatment 
plan goals outlined in the clinical trial. The parotids were sufficiently shielded but the spinal 
cord was not protected sufficiently resulting into a large a volume receiving the same dose as 
the target. Furthermore, the target coverage was compromised resulting significant non-
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uniformity, with several cold and hot spots. Because of the clinical inappropriateness of the 
passive scattering plan the proton clinician responsible for approving the treatment plans for 
this project rejected it, and therefore the project moved on focused on the spot scanning 
treatments and no measurements were made with the H&N phantom.  
3.3 Patient QA of the Phantom 
The regular patient QA procedure performed in the PTC clinic was done on the 
phantom in order to check the treatment plan. Two sets of measurements were taken for every 
beam used in the pencil beam plan. Measurements were taken in shallow and deep depths, as 
shown in Figure 3.7 and Figure 3.8 respectively. The depths were chosen to be in regions with 
low doses gradients on the dose profiles inside the target. Both measurements were done using 
a MatriXX device with added solid water buildup to correctly place the measurements’ depth 
on the active ion chamber region. The PTC uses a separate software to run a gamma analysis 
with a criteria of 3%,3mm. Table 6 shows the depths selected and the gamma analysis results. 
The full patient QA report can be found in the Appendix.  
 
Figure 3-7: Shallow measurements set up using MatriXX IBA on a rotating 
device 
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Figure 3-8: Shallow measurements set up using MatriXX IBA on treatment 
couch 
 Beam Depth (cm) Gamma Index 
(3%,3mm) 
Posterior 
5.0 100 
7.9 100 
Right 
Oblique 
2.0 95.1 
8.4 100 
Left 
Oblique 
5.0 99.4 
8.4 100 
Table 6: Measurements depths and gamma index results from Patient QA done 
on Phantom 
 
3.4 Spot Scanning Measurements 
3.4.1 Point Dose Comparison 
For the absolute dose comparison, the phantom TLD doses from each of the spot 
scanning irradiation trials were compared to the calculated doses from the Eclipse treatment 
planning system. The RBE weighted dose to the superior target TLD was calculated by the 
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treatment plan to be 646.2 cGy(RBE), and 648.6 cGy(RBE) for the inferior target TLD. The 
values for calculated and measured target doses (cGy(RBE)), as well as the ratio of the 
measured to calculated doses, are given in Table 7 for four different irradiation trials. Trial 1, 
and trials 4-6 were irradiated on two separate dates. 
   
TLD Location 
TPS 
Dose Calculated 
 
Dose Measured 
Ratio 
[Meas./Calc.] 
TRIAL 1 Target Superior 646.2 654.3 1.013 
Target Inferior 648.6 627.9 0.968 
TRIAL 4 Target Superior 646.2 631.6 0.977 
Target Inferior 648.6 638.1 0.984 
TRIAL 5 Target Superior 646.2 631.8 0.978 
Target Inferior 648.6 625.6 0.964 
TRIAL 6 Target Superior 646.2 634.8 0.982 
Target Inferior 648.6 646.3 0.996 
Table 7: Target point dose comparison between treatment planning system and 
TLDs for all irradiation trials 
Trials 2 and 3 were not used in the final analysis. Trials 2 and 3 hade acceptable TLD 
readings for the target but vast OAR dose discrepancies when compared to the TPS, as shown 
in Table 8. The parotids received twice the dose predicted when compared to the TPS and the 
cord was given target dose. After investigating these inconsistencies, it was discovered that 
the IMPT plan had been delivered incorrectly for trials 2 and 3 and that was the reason why 
the results were poor and did not agree with the calculated dose distributions from the planning 
system. The couch had a 20 degree rotation on each oblique beam and that couch kick was 
not employed during the irradiations. Figure 3.7 shows a comparison of the axial trial’s 1 and 
3 films. The film clearly displays the issue where the dose on Trial 3 is significantly less 
conformal than on Trial 1, which would explain why the OARs around the target received 
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higher than predicted doses. The couch rotation was corrected for irradiations 4, 5 and 6 and 
the results were much more consistent and accurate for the doses delivered to the target and 
especially critical structures.  
  TLD Location Dose Calculated - 
TPS 
Dose measured Ratio 
[Meas./Calc.] 
TRIAL 2 Target Superior 646.2 656.0 1.015 
Target Inferior 648.6 637.0 0.982 
Parotid Left 250.2 453.6 1.813 
Parotid Right 206.4 459.0 2.224 
Cord 503.4 604.9 1.202 
TRIAL 3 Target Superior 646.2 657.0 1.018 
Target Inferior 648.6 633.6 0.977 
Parotid Left 250.2 443.4 1.772 
Parotid Right 206.4 459.0 2.224 
Cord 503.4 604.5 1.201 
Table 8: TLD readings for faulty trials 2 and 3. 
 
(a) Trial 1 Axial film    (b) Trial 3 Axial film 
Figure 3-9: Axial film scans showing the difference in dose distribution 
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The superior and inferior target TLD doses for the correctly delivered irradiation trials 
1, 4, 5 and 6 were averaged and are shown in Table 9. The measured to calculated ratios 
showed good agreement between the treatment planning system and the average TLD 
measurements, 1.6% for the superior target and 1.4% for the inferior. Both target TLD ratios 
are well below IROCs acceptance criterion of ±5% dose agreement tolerance. The percent 
standard deviation for the TLD measurements combined (trials 1, 4, 5 and 6) was 1.52%, and 
therefore meet the 3% reproducibility criterion established in the hypothesis.   
 TPS Dose [cGy] Average Dose Values between Trials 1, 4, 5 and 6  [cGy] 
Ratio 
[Meas./Calc.] 
Target Superior 646.2 636.1 0.984 
Target Inferior 648.6 639.6 0.986 
Table 9: Average target TLD doses for the relevant trials 1, 4 and 5 and 
measured to calculated ratios 
The target TLD doses were 1.6% and 1.4% low when compared to the TPS 
calculations. One possible explanation for this outcome could be that proton therapy treatment 
planning systems tend to overestimate target doses by as much as 3.5% for head and neck 
patients when compared to Monte Carlo simulations as described by Schuemann J. [52] 
Margins are used in order to account for the inaccurate predictions of the proton range and 
absolute dose but due to the high complexity of the head and neck geometries and 
inhomogeneities, these malignancies  show the largest dose variations (3-4%) between TPS 
and Monte Carlo. [52] Our measurements support these findings and would agree with the 
Monte Carlo dose calculations. 
The values for the calculated and measured doses for the critical structures in the 
phantom are shown in Table 10 along with the ratio of the measured to calculated doses. Table 
11 shows the average OARs values for trials 1, 4, 5 and 6. A TLD was also inserted into the 
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oral cavity in order to ascertain that the dose delivered around the mandible and teeth were 
kept low, since that is a very sensitive region in patients. That TLD was not part of the 
treatment plan and therefore a measured to calculated ratio could not be established. 
Nevertheless, the average reading between all the trials for the mouth TLD was 1.4 cGy, well 
below clinical constraints. 
  TLD Location Dose Calculated - TPS Dose measured Ratio 
[Meas./Calc.] 
TRIAL 1 Parotid Left 250.2 274.8 1.098 
Parotid Right 206.4 199.1 0.965 
Cord 503.4 493.2 0.980 
TRIAL 4 Parotid Left 250.2 273.5 1.093 
 Parotid Right 206.4 209.3 1.014 
 Cord 503.4 498.5 0.990 
TRIAL 5 Parotid Left 250.2 285.3 1.140 
 Parotid Right 206.4 209.6 1.015 
 Cord 503.4 486.5 0.966 
TRIAL 6 Parotid Left 250.2 311.1 1.243 
Parotid Right 206.4 209.8 1.016 
Cord 503.4 492.7 0.979 
Table 10: Critical Structure point dose comparison between treatment planning 
system and TLDs 
 TPS Dose [cGy] Average Dose Values between Trials 1,4, 5 and 6  [cGy] 
Ratio 
[Meas./Calc.] 
Parotid Left 250.2 286.1 1.143 
Parotid Right 206.4 206.9 1.002 
Cord 503.4 492.7 0.978 
Table 11: Average OARs TLD doses for the relevant trials 1, 4 and 5 and 
measured to calculated ratios 
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It is also possible to notice that the OAR ratios showed good agreement. The ratios for 
the parotid doses were 14.3% and 0.2% high for the left and right parotids respectively, while 
the cord had a dose agreement of 2.2%. It is noticeable that the left parotid has the poorest 
agreement with the TPS predicted doses. One possible explanation for that is that the left 
parotid was located in a higher dose gradient region than the right parotid, seen on the axial 
screenshot of the treatment plan in Figure 3.10. That means that very small shifts in the setup 
could represent large dose difference in the TLD results between the several trials.  
3.4.2 Relative Dose Comparison 
The 2D dose distributions were analyzed by comparing the dose distribution calculated 
by the treatment planning system and the one measured by the phantom films in the axial and 
sagittal planes. The film dose distributions were normalized to the TLD doses at the locations 
of the TLD capsules in the target. The film and CT registration using the pin pricks on the 
Figure 3-10: Axial screenshot of treatment plan with isodose lines shown to be 
on top of the left parotid TLD. 
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films was achieved with an RMS < 1mm for all irradiation trials. The RMS error ranged from 
0.24 mm to 0.98 mm for the film registration and the 3D RMS used in analysis was 0.54 mm 
for the CT images. The gamma index acceptance criteria hypothesized in this project is 
±7%/4mm, nevertheless tighter criteria of ±5%/3mm, ±5%/4mm were also evaluated. The 2D 
gamma analysis results showing the percent of pixels meeting the various acceptance criteria 
for irradiation trials 1, 4, 5 and 6 are listed in Table 12. All trials pass the 85% criteria used at 
IROC for the gamma index proposed in the hypothesis (±7%/4 mm). As expected, tighter 
criteria show lower passing rates, but still perform well. The sagittal film in trial 5 is the only 
one that does not pass the ±5%/4mm criterion, with only 81.8% of pixels passing. The percent 
standard deviation for the gamma passing rates combined (trials 1, 4, 5 and 6) was 2.43%, and 
therefore also meet the 3% reproducibility criterion established in the hypothesis.   
  2D Gamma Percentage of Pixels Passing 
    5%, 3mm 5%, 4 mm 7%, 4mm 
TRIAL 1 Axial 86.3% 91.0% 95.5% 
Sagittal  82.6% 87.6% 94.2% 
TRIAL 4 Axial 91.0% 94.0% 97.3% 
Sagittal  80.2% 87.0% 93.2% 
TRIAL 5 Axial 82.1% 88.6% 93.4% 
Sagittal  76.0% 81.8% 90.0% 
TRIAL 6 Axial 91.0% 93.4% 96.2% 
Sagittal  80.6% 86.4% 92.7% 
Table 12: 2D gamma analysis pass rates for the spot scanning irradiations 
The dose map obtained in the gamma analysis shows the same general distribution of 
passing and failing pixels through the four trials. Pixels that have a calculated gamma of less 
than 1 are considered to pass and are assigned the color light blue/blue. As it can be seen in 
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Figure 3.11, the largest amount of pixels failing fall within the target and in the posterior 
portion of the film plane. The pixels at the bottom could be falling because of uncertainty 
present in the calculation of the end of the proton beam range. Both oblique beams conform 
to the isodose lines creating a bump in the posterior part of the axial film, as seen in Figure 
3.12. That area coincides with the failing area in the gamma dose map. Similarly to the axial 
films, on Figure 3.13, the sagittal films show the majority of the failing pixels to be located 
inside the target and in the posterior region on the film. The complete set of gamma indexes 
for all trials and criteria can be found in the Appendix. 
 
 
 
(b) Trial 1 Axial 95.5%  (b) Trial 4 Axial 97.3% 
(c) Trial 5 Axial 93.4%   (d) Trial 6 Axial 96.2% 
Figure 3-11: Axial views for Trials 1, 4, 5 and 6 for 7%,4mm.   
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Figure 3-12: Slice of treatment plan showing isodose lines. 
 
 
(a) Trial 1 Sagittal 94.2%     (b)Trial 4 Sagittal 93.2%    
(b) Trial 5 Sagittal 90.0%     (d) Trial 6 Sagittal 92.7% 
Figure 3-13: Sagittal views for Trials 1, 4, 5 and 6 for 7%,4mm. 
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The gamma analysis results for the faulty trials 2 and 3 were also performed for the 
criteria (7%/4mm) used in this project and the pixel passing percentages are shown in Table 
13. It is noticeable that neither trials passed IROC’s standard passing rate of 85% of pixels. 
Both results were similar to each other and well below trials 1, 4, 5 and 6. Figure 3.14 shows 
the large areas in the axial and sagittal dose maps failing the gamma criteria. This result can 
demonstrate part of the consequences of how the wrongful application of couch angles can 
affect the treatment delivery. The harm of misplacing the couch during treatment was also 
demonstrated in the point dosimetry in the previous section. The target TLDs, placed in the 
center, showed good conformance with the treatment plan, with ratios within IROCs 
acceptance standards. However, the OARs, situated more superficial to the target, had large 
discrepancies in their TLD readings. This could be extrapolated to a real life scenario where, 
if couch angles were overlooked tumor control would be achieved but along with very high 
healthy tissue toxicity to the patient.  
 
  2D Gamma Percentage of Pixels Passing 
    7%, 4mm 
TRIAL 2 
 
Axial 74.4% 
Sagittal  78.2% 
TRIAL 3 
 
Axial 79.5% 
Sagittal  79.5% 
Table 13: 2D gamma analysis pass rates for trials 2 and 3 along with their 
averages 
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(a) Trial 2 Axial 74.5%     (b)Trial 2 Sagittal 78.2%    
(b) Trial 3 Axial 79.5%     (d) Trial 3 Sagittal 79.5% 
Figure 3-14: Axial and Sagittal dose maps for the faulty trials 2 and 3. 
3.4.3 Profile Analysis 
Dose profiles comparing the TPS dose with the measured film dose for the trials were 
also analyzed. The film profile was obtained from the same IROC in-house software used for 
the film analysis. The film dose curve was smoothed by averaging each data point with 10 
values above and below the particular point. Figure 3.16 through Figure 3.19 show the dose 
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profiles for Trial 1. The left to right profiles cross the target and parotids but not the spinal 
cord, while the anterior posterior profiles miss the parotids and cross the cord structure. The 
inferior superior profiles pass through the target inside the TLD slots. These profile references 
can be seen in Figure 3.15 where the representation of the path of the profiles is shown. The 
additional profiles can be seen in the Appedix seccion. All profiles analyzed showed the 
general shape predicted in the TPS, presenting no setup shifts or clear proton beam range 
issues.  
 
Figure 3-15: Profile Labeling of the orientation of the 4 different profiles. 
These profiles also show the areas that failed the gamma analysis. The previous section 
showed that most pixels failed the axial films inside the target and towards the posterior 
section on the phantom. Both AP profiles show the largest discrepancy between the TPS and 
film dose curves to be within the plateau of the target and behind the cord. 
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Figure 3-16: Axial (left to right) dose profile comparing the TPS dose with the 
measured film dose for Trial 1 
 
Figure 3-17: Axial (anterior to posterior) dose profile comparing the TPS dose 
with the measured film dose for Trial 1 
 
Figure 3-18: Sagittal (inferior to superior) dose profile comparing the TPS dose 
with the measured film dose for Trial 1 
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Figure 3-19: Sagittal (anterior to posterior) dose profile comparing the TPS 
dose with the measured film dose for Trial 1 
Distance to agreement (DTA) for all the AP dose profiles were also measured and are 
shown below in Table 14. They were taken comparing the film dose curve to the TPS dose 
curve at the midpoint between the spinal cord and target. That was done in order to check the 
conformality of the dose distribution in that high dose gradient region. The film registration 
procedure has an uncertainty of 1 mm, but the all fall within IROC’s acceptance criteria of 4 
mm.  
 Profile 
Orientation 
DTA (mm) 
TRIAL 1 Axial AP  1.0 
Sagittal AP 0.3 
TRIAL 4 Axial AP  0.6 
Sagittal AP 1.9 
TRIAL 5 Axial AP  1.6 
Sagittal AP 3.3 
TRIAL 6 Axial AP  0.6 
Sagittal AP 2.3 
Table 14: Distance to agreement for all AP dose profiles 
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3.4.4 TLD Verification 
A TLD verification procedure was performed in order to check the proton beam output 
at the same gantry the irradiations were performed. A TLD block, used at IROC for the same 
purpose, was loaded with 5 TLDs and placed in the center of the SOBP. In order to achieve 
the correct depth, blocks of acrylic were added in front on the block. The block identification 
number was E316 and the total dose delivered was 220.3 cGy(RBE). The TLD doses obtained 
are shown in Table 15 along with the measured to calculated ratios. 
 Dose 
measured 
Dose 
Calculated TPS
Ratio 
[Meas./Calc.] 
TLD 1 216.78 220.30 0.984 
TLD 2 213.10 220.30 0.967 
TLD 3 215.56 220.30 0.979 
TLD 4 217.24 220.30 0.986 
TLD 5 217.75 220.30 0.988 
Average 0.980 
Table 15: Measured TLD doses for the beam output check and the measured to 
calculated ratios. 
The output verification was completed with TLDs from the same batch used in the 
irradiations. Similarly to the pattern observed in the irradiations, the dose delivered is lower 
than what predicted. This could represent one potential reason for why the TLD values 
obtained in the irradiation trials were slightly lower than the TPS or, for the same reason as 
for the trials, the TPS could be overestimating the planned doses.  
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4 Conclusions 
The hypothesis that an anthropomorphic head and neck phantom can be designed and 
built to evaluate proton therapy treatment procedures for oropharyngeal cancer with an 
agreement between measured and calculated doses of ±7%/4mm with a reproducibility of 3% 
was met for the pencil beam treatment plan. The phantom was used in four end to end scanning 
treatments and they all passed the 85% pixel passing gamma and IROC’s TLD acceptance 
criteria of ±5% dose agreement tolerance. The scattering plan was not able to be delivered due 
its lack of clinical relevance and therefore did not have an analysis performed.  
The phantom was successfully used as a QA tool with the purpose of simulating a head 
and neck disease. The horse shoe shaped insert and structures inside were made of solid water 
and blue water respectively. The design included the oropharyngeal target to be treated and 
three OARs to be protected, two parotids and a spinal cord. Spot scanning and passive 
scattering treatment plans were created but due to the lack of clinical relevance of the passive 
plan, it was determined that it ought not to be delivered. The pencil beam plan achieved 
adequate target coverage and acceptable parotid doses. The maximum cord dose exceeded the 
dose restriction because of the tight fit of the insert. 
For the point dosimetry, the average dose values between trials 1, 4, 5 and 6 were 
636.1 cGy and 639.6 cGy for the superior and inferior target TLDs, respectively. The 
measured to calculated ratios were 0.984 for the superior target TLD and 0.986 for the inferior 
target TLD. Being only 1.6% and 1.4% lower than expected, both TLD results fall within 
IROC’s acceptance criteria. The relative dose comparison was performed using a gamma 
index of ±7%/4 mm, and all trials passed the 85% pixel passing criteria established at IROC. 
Trial 1 axial being 95.5%, sagittal 94.2%, trial 4 axial being 97.3%, sagittal 93.2%, trial 5 
74 
 
axial 93.4%, sagittal 90.0%, and finally trial 6 axial being 96.2 and sagittal 92.7%. As 
expected, the tighter criteria (±5%,4mm and ±5%,3mm) had poorer passing rates. The tighter 
criteria are not suitable for this particular project due to the inherent uncertainty in the 
detectors used and the nature of the phantom design. The ICRU recommends a radiation dose 
agreement of ±5% compared to patient treatment plans. However, the TLDs used in the project 
have 1.5% uncertainty in their dose measurements. That means that institutions that deliver 
doses close to the ±5% ICRU expectations need extra room to be considered acceptable due 
to the TLD uncertainty. In addition, the phantom itself contains large heterogeneities, such as 
bony structures and air cavities that make it harder to obtain perfect measurements or pass 
tighter criteria. Like the dose criteria, there is uncertainty in the distance to agreement portion 
of the film measurements. The film registration process is allowed a 1 mm uncertainty while 
registering the film pin pricks and TLD’s positions. Also, similar to the photon H&N phantom, 
there are very high dose gradients in these treatment plans, demanding a 4mm criteria to more 
complex of the phantom designs.  
Moving forward, a new insert should be designed where the target and organs at risk 
are placed slightly farther from each other. The cord could be moved down a centimeter and 
the target could be shrunken down slightly. That would aim to allow for a passive scattering 
plan to be successfully created and delivered to the phantom. Another possible advantage of 
constructing an alternative insert would be to more easily achieve clinical constraints for the 
OARs. The current design did not allow for the pencil beam plan to effectively protect the 
spinal cord maximum dose, thus a new design could be created to addressed that issue as well. 
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5 Appendix 
5.1 Gamma Analysis 
5.1.1 7% 4 mm Criteria 
 
Figure 5-1: TRIAL 1 - Axial 95.5%  (7%, 4mm) 
 
Figure 5-2: TRIAL 1 - Sagittal 94.2% (7%, 4mm) 
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Figure 5-3: TRIAL 4 – Axial 97.3% (7%, 4mm) 
 
 
 
Figure 5-4: TRIAL 4 – Sagittal 93.9%  (7%, 4mm) 
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Figure 5-5: TRIAL 5 – Axial 93.4%  (7%, 4mm) 
 
Figure 5-6: TRIAL 5 – Sagittal 90.0% (7%, 4mm) 
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Figure 5-7: TRIAL 6 – Axial 96.2%  (7%, 4mm) 
 
Figure 5-8: TRIAL 6 – Sagittal 92.7% (7%, 4mm) 
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5.1.2 5% 4 mm Criteria 
 
Figure 5-9: TRIAL 1 - Axial 91.0%  (5%, 4mm) 
 
Figure 5-10: TRIAL 1 - Sagittal 87.62%  (5%, 4mm) 
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Figure 5-11: TRIAL 4 - Axial 94.0 %  (5%, 4mm) 
 
 
 
Figure 5-12: TRIAL 4 - Sagittal 87.0%  (5%, 4mm) 
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Figure 5-13: TRIAL 5 - Axial 88.5%  (5%, 4mm) 
 
 
 
Figure 5-14: TRIAL 5 - Sagittal 81.8%  (5%, 4mm) 
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Figure 5-15: TRIAL 6 - Axial 93.4%  (5%, 4mm) 
 
 
Figure 5-16: TRIAL 6 – Sagittal 86.4%  (5%, 4mm) 
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5.1.3 5% 3 mm Criteria 
 
Figure 5-17: TRIAL 1 - Axial 86.27%  (5%, 3mm) 
 
 
Figure 5-18: TRIAL 1 – Sagittal 82.61%  (5%, 3mm) 
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Figure 5-19: TRIAL 4 - Axial 90.69%  (5%, 3mm) 
 
 
Figure 5-20: TRIAL 4 – Sagittal 80.2%  (5%, 3mm) 
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Figure 5-21: TRIAL 5 - Axial 82.1%  (5%, 3mm) 
 
 
Figure 5-22: TRIAL 5 – Sagittal 76.0%  (5%, 3mm) 
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Figure 5-23: TRIAL 6 - Axial 91.0%  (5%, 3mm) 
 
 
Figure 5-24: TRIAL 6 – Sagittal 80.6%  (5%, 3mm) 
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5.1.4 7% 4 mm Criteria for the Faulty Trials 
 
Figure 5-25: TRIAL 2 – Axial 74.5% (7%, 4mm) 
 
 
Figure 5-26: TRIAL 2 – Sagittal 78.2% (7%, 4mm) 
88 
 
 
Figure 5-27: TRIAL 3 – Axial 79.5% (7%, 4mm) 
 
 
Figure 5-28: TRIAL3 – Sagittal 79.5% (7%, 4mm) 
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5.2 Film Profiles 
5.2.1 Trial 1 Profiles 
 
Figure 5-29: Axial (left to right) dose profile comparing the TPS dose with the 
measured film dose for Trial 1 
 
Figure 5-30: Axial (anterior to posterior) dose profile comparing the TPS dose 
with the measured film dose for Trial 1 
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Figure 5-31: Sagittal (inferior to superior) dose profile comparing the TPS dose 
with the measured film dose for Trial 1 
 
Figure 5-32: Sagittal (anterior to posterior) dose profile comparing the TPS 
dose with the measured film dose for Trial 1 
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5.2.2 Trial 4 Profiles 
 
Figure 5-33: Axial (left to right) dose profile comparing the TPS dose with the 
measured film dose for Trial 4 
 
Figure 5-34: Axial (anterior to posterior) dose profile comparing the TPS dose 
with the measured film dose for Trial 4 
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Figure 5-35: Sagittal (inferior to superior) dose profile comparing the TPS dose 
with the measured film dose for Trial 4 
 
Figure 5-36: Sagittal (anterior to posterior) dose profile comparing the TPS 
dose with the measured film dose for Trial 4 
 
5.2.3 Trial 5 Profiles 
 
Figure 5-37: Axial (left to right) dose profile comparing the TPS dose with the 
measured film dose for Trial 5 
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Figure 5-38: Axial (anterior to posterior) dose profile comparing the TPS dose 
with the measured film dose for Trial 5 
 
Figure 5-39: Sagittal (inferior to superior) dose profile comparing the TPS dose 
with the measured film dose for Trial 5 
 
Figure 5-40: Sagittal (anterior to posterior) dose profile comparing the TPS 
dose with the measured film dose for Trial 5 
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5.2.4 Trial 6 Profiles 
 
Figure 5-41: Axial (left to right) dose profile comparing the TPS dose with the 
measured film dose for Trial 6 
 
Figure 5-42: Axial (anterior to posterior) dose profile comparing the TPS dose 
with the measured film dose for Trial 6 
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Figure 5-43: Sagittal (inferior to superior) dose profile comparing the TPS dose 
with the measured film dose for Trial 6 
 
Figure 5-44: Sagittal (anterior to posterior) dose profile comparing the TPS 
dose with the measured film dose for Trial 6 
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5.3 PTC – H Phantom QA Report 
Department of Radiation Physics, Division of Radiation Oncology M.D. Anderson 
Cancer Center / Proton Therapy Center Houston 
Scanning Proton Beam Patient Specific QA Report 
Patient: ProtonHead, db MRN: zzIROC
Db Protonhead is to receive treatment with proton therapy using the scanning beam 
in G3. The multi-field optimized treatment plan consists of 3 fields. The plan calls for 6 cGy 
(RBE) delivered to the GTV in 1 fraction. The parameters of the fields are listed in Table 1.  
Prescription GTV 
(cc) 
(cc) Field Nominal 
Range 
(cm) 
Nominal 
SOBP 
(cm) 
Max 
E 
(MeV) 
Layers Total 
Spots
MU 
Isodose 
Line (%) 
 
96.7 0 DPAPB 14.97 9.09 144.9 36 3851 135.94 
ERAPB 11.95 8.99 131 40 3309 114.45 
FLAPB 12.55 8.87 132.8 40 3742 131.9 
 
Table 1: Treatment field parameters. 
Comprehensive quality assurance measurements of dose distribution were performed for this 
patient's treatment plan on July 09, 2016. The results are discussed below. 
(1) Dose measurements delivered through MOSAIQ™ at the planned gantry angle for 
each field 
 
In the Eclipse treatment planning system (TPS), a verification plan was created on a 
digital water phantom. The SSDs and the measurement depths for each field are listed in Table 
2. The plan provided a calculated 3D dose distribution for each field. The 2D dose-
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distribution-plane perpendicular to the beam direction and intersecting with the isocenter was 
extracted to compare with measurements. A 2D ion-chamber-array detector (MatriXX) was 
mounted to the couch via a rotatable attachment and then used to measure the same dose-
planes from the treatment-prescribed gantry angles. The measured 2D physical dose 
distributions were corrected for daily machine output variation, and compared with the TPS-
calculated physical dose distributions. Results are shown in Figures 1 - 6. All measurements 
agreed reasonably well with over 95% of pixels passing the 3%/3 mm dose/distance 
agreement criteria.  
 
Field Gantry 
angle 
(°) 
Snout 
Position 
(cm) 
SSD 
(cm) 
Depth 
(cm) 
Gamma index 
(3% /3mm) 
DPAPB 180 38 265 5 100.00% 
ERAPB 295 38 268 2 95.10% 
FLAPB 65 38 265 5 99.40% 
 
Table 2. Gamma index passing rate for fields delivered at treatment gantry 
angles. 
(2) TPS dose calculations compared to HPlusQA 
The verification plan was exported from Eclipse to HPlusQA, a patient specific QA 
system with an independent dose calculation algorithm (Mackin et al.Med. Phys. 40, 121708, 
2013). The 3D dose distributions from Eclipse were then compared to dose distributions 
calculated by HPlusQA. Figure 7 shows a dose depth profile comparison of the Eclipse and 
HPlusQA calculations for each field in the verification plan. The 2D gamma index was used 
to compare the Eclipse and the HPlusQA dose calculations in a virtual uniform water phantom. 
The results of these comparisons are given in Table 3. The gamma pass rate for HPlusQA 
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and Eclipse using 3%/3 mm dose/distance agreement criteria is 100% for all examined 
depths.  
 Beam Depth (cm) Gamma Index 
(3%,3mm) 
Posterior 
5.0 100 
7.9 100 
Right 
Oblique 
2.0 100 
8.4 100 
Left 
Oblique 
5.0 100 
8.4 100 
 
Table 3. HPlusQA vs. Eclipse gamma index passing percentages. DTA is 
distance to agreement. 
(3) Dose measurements delivered in physics mode for each field 
The MatriXX ion chamber array was used to measure the 2D dose distribution in the 
solid water phantom at several depths for each field. The gamma index scores comparing these 
measured dose planes to dose planes calculated by Eclipse are listed in Table 4, and the results 
are shown in Figures 8 - 13. Also, point doses extracted from the measured dose planes are 
compared to dose profiles (parallel to the beam axis) extracted from both Eclipse and 
HPlusQA dose calculations in Fig. 7. The measurements generally agree with Eclipse with 
all examined depths having gamma pass rates greater than 95% using 3%/3 mm 
dose/distance agreement criteria.  
 
 Beam Depth (cm) Gamma Index 
(3%,3mm) 
Posterior 
5.0 100 
7.9 100 
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Right 
Oblique 
2.0 95.1 
8.4 100 
Left 
Oblique 
5.0 99.4 
8.4 100 
 
Table 4. Gamma index passing percentages for dose planes calculated using a 
MatriXX ion chamber array compared to dose planes calculated with Eclipse. 
Reported by: 
Matthew 
D. Kerr 
ID#: 
186421 
Certification: BS Physics 
Date: 
07/10/2016 
 
Reviewed by: 
[PHYS. 
NAME] 
ID#: Certification:[B.A.,MS,PhD] 
Date: 
[DATE] 
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5.3.1.1 MOSAIQ™ Measurements: MatriXX versus Eclipse (3 mm, 3%), Field: 
DPAPB 
Figure 1: Gamma analysis for field DPAPB (gantry = 180°). Upper left: dose plane 
measured with a MatriXX ion chamber array; lower left: dose plane calculated with Eclipse; 
upper right: gamma index map; lower right: histogram of gamma index values for the test 
pixels. 100.0% of the pixels passed the 3%/3 mm dose/distance agreement criteria. The 
measurements were made at a water equivalent depth of 5.0 cm.  
 
101 
 
 
Figure 2: Isodose line-comparison of dose measured with a MatriXX ion chamber 
array and dose calculated with Eclipse. The measurements were made at a water equivalent 
depth of 5.0 cm.  
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5.3.1.2 MOSAIQ™ Measurements: MatriXX versus Eclipse (3 mm, 3%), Field: 
ERAPB 
Figure 3: Gamma analysis for field ERAPB (gantry = 295°). Upper left: dose plane 
measured with a MatriXX ion chamber array; lower left: dose plane calculated with Eclipse; 
upper right: gamma index map; lower right: histogram of gamma index values for the test 
pixels. 95.1% of the pixels passed the 3%/3 mm dose/distance agreement criteria. The 
measurements were made at a water equivalent depth of 2.0 cm.  
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Figure 4: Isodose line-comparison of dose measured with a MatriXX ion chamber 
array and dose calculated with Eclipse. The measurements were made at a water equivalent 
depth of 2.0 cm.  
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5.3.1.3 MOSAIQ™ Measurements: MatriXX versus Eclipse (3 mm, 3%), Field: 
FLAPB 
Figure 5: Gamma analysis for field FLAPB (gantry = 65°). Upper left: dose plane 
measured with a MatriXX ion chamber array; lower left: dose plane calculated with Eclipse; 
upper right: gamma index map; lower right: histogram of gamma index values for the test 
pixels. 99.4% of the pixels passed the 3%/3 mm dose/distance agreement criteria. The 
measurements were made at a water equivalent depth of 5.0 cm.  
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Figure 6: Isodose line-comparison of dose measured with a MatriXX ion chamber 
array and dose calculated with Eclipse. The measurements were made at a water equivalent 
depth of 5.0 cm.  
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5.3.1.4 Treatment Field Profiles 
 
 
 
 
Figure 7: Comparisons of dose depth profiles calculated by Eclipse and HPlusQA. 
Point doses extracted from dose planes measured with a Matrixx ion chamber array are 
indicated using black dots. The error bars extending from the black dots represent 3% and 3-
mm uncertainties in the horizontal and vertical directions respectively.  
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5.3.1.5 Depth Measurements: MatriXX versus Eclipse (3 mm, 3%), Field: DPAPB, 
Depth: 7.9 cm 
Figure 8: Gamma analysis for field DPAPB. Upper left: dose plane measured with a 
MatriXX ion chamber array; lower left: dose plane calculated with Eclipse; upper right: 
gamma index map; lower right: histogram of gamma index values for the test pixels. 100.0% 
of the pixels passed the 3%/3 mm dose/distance agreement criteria.  
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Figure 9: Isodose line-comparison of dose measured with a MatriXX ion chamber 
array and dose calculated with Eclipse. The measurements were made at a water equivalent 
depth of 7.9 cm.  
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5.3.1.6 Depth Measurements: MatriXX versus Eclipse (3 mm, 3%), Field: ERAPB, 
Depth: 8.4 cm 
Figure 10: Gamma analysis for field ERAPB. Upper left: dose plane measured with 
a MatriXX ion chamber array; lower left: dose plane calculated with Eclipse; upper right: 
gamma index map; lower right: histogram of gamma index values for the test pixels. 100.0% 
of the pixels passed the 3%/3 mm dose/distance agreement criteria.  
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Figure 11: Isodose line-comparison of dose measured with a MatriXX ion chamber 
array and dose calculated with Eclipse. The measurements were made at a water equivalent 
depth of 8.4 cm.  
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5.3.1.7 Depth Measurements: MatriXX versus Eclipse (3 mm, 3%), Field: FLAPB, 
Depth: 8.4 cm 
Figure 12: Gamma analysis for field FLAPB. Upper left: dose plane measured with 
a MatriXX ion chamber array; lower left: dose plane calculated with Eclipse; upper right: 
gamma index map; lower right: histogram of gamma index values for the test pixels. 100.0% 
of the pixels passed the 3%/3 mm dose/distance agreement criteria.  
 
112 
 
 
Figure 13: Isodose line-comparison of dose measured with a MatriXX ion chamber 
array and dose calculated with Eclipse. The measurements were made at a water equivalent 
depth of 8.4 cm.  
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